Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, gives an update on the Phase III MOMENTUM study which is investigating momelotinib versus danazol in patients with myelofibrosis who have failed JAK inhibition and are transfusion-dependent and anemic. The study aims to improve spleen symptoms and anemia. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
